Marinus Pharmaceuticals shares are trading lower after the company announced its Phase 3 TrustTSC trial of Oral Ganaxolone did not meet its primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
Marinus Pharmaceuticals' shares fell after the company announced that its Phase 3 TrustTSC trial of Oral Ganaxolone did not meet its primary endpoint.
October 24, 2024 | 1:44 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Marinus Pharmaceuticals' stock is trading lower due to the failure of its Phase 3 TrustTSC trial of Oral Ganaxolone to meet the primary endpoint.
The failure of a Phase 3 trial is a significant setback for a pharmaceutical company, as it can delay or prevent the approval of a new drug. This news likely led to a decrease in investor confidence, resulting in a drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100